Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Recordati has received approval for Zan-Extra, a fixed combination of lercanidipine and enalapril indicated for the treatment of hypertension, in Australia.
Subscribe to our email newsletter
The Australian Register of Therapeutic Goods communicated its decision to approve the registration submitted by licensee Solvay Biosciences of Zan-Extra in its two dosage forms containing lercanidipine 10mg/enalapril 10mg and lercanidipine 10mg/enalapril 20mg. The launch in Australia of this new product originated by Recordati is planned to take place in April.
Giovanni Recordati, chairman and CEO of Recordati, said: “We are expecting the outcome of the mutual recognition procedure in Europe shortly and this will allow us to launch the product throughout the EU.”